Zhi Ye Wang

Oct 24, 2024 | virologyj.biomedcentral.com | Haidi Wu |Jiaxin Tian |Wenbo Shi |Zhi Ye Wang |Yanjun Du |Hongwei Xu | +8 more

In this observational, real-world study, patients who received tixagevimab/cilgavimab from July 9, 2022, to December 30, 2022, in Hainan, China, were included. The inclusion criteria were patients who received tixagevimab/cilgavimab either before the initiation of the study or were prescribed with tixagevimab/cilgavimab thereafter. The patients participating in interventional clinical trials for SARS-CoV-2 prophylactics or treatments were excluded.